• Cellular Biomedicine Group Inc., of Palo Alto, Calif., reported positive interim results of its Phase I/IIa trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for knee osteoarthritis. The study, which is testing the safety and efficacy of intra-articular injections of autologous haMPCs to reduce inflammation and repair damaged joint cartilage, showed preliminary findings of improvement (P<0.05) from baseline in clinical scores for SF-36, NRS-11 and WOMAC osteoarthritis indices.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter